Collaboration Revenue (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 |
Aug. 31, 2020 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Jun. 30, 2024 |
Jun. 30, 2023 |
Sep. 30, 2023 |
Sep. 30, 2022 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Collavorative arrangement right and obligation | New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field | New Life is also obligated to pay a non-refundable deferred license fee of an additional $1.0 million at the time of the satisfaction of certain milestones, as well as potential additional milestone payments to the Company of up to $19.0 million subject to the achievement of certain development and commercialization milestones. In addition, during the Royalty Term (as defined below), New Life is obligated to pay the Company tiered double-digit royalties ranging from 12% to 30% based on annual net sales of Products in the Exclusive Territory. The “Royalty Term” means, on a Product-by-Product and a country-by-country basis in the Exclusive Territory, the period commencing on the date of the first commercial sale (subject to certain conditions) of such Product in such country in the Exclusive Territory and continuing until New Life ceases commercialization of such Product in the DIPN Field | ||||||
| Performance obligation | $ 1,000,000.0 | $ 1,000,000.0 | ||||||
| Collaboration revenue | $ 36,850 | 18,626 | $ 110,550 | 147,805 | $ 349,943 | |||
| License Agreement [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Proceeds for negotiate license agreement | $ 500,000 | |||||||
| New Life Agreement [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Proceeds for negotiate license agreement | $ 500,000 | |||||||
| Future milestone payments | 1,000,000.0 | 1,000,000.0 | 1,000,000.0 | |||||
| Milestone payments | $ 19,000,000.0 | $ 19,000,000.0 | $ 19,000,000.0 | |||||
| New Life Agreement [Member] | Minimum [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Royalties, percentage | 12.00% | 12.00% | 12.00% | |||||
| New Life Agreement [Member] | Maximum [Member] | ||||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||||
| Royalties, percentage | 30.00% | 30.00% | 30.00% | |||||